Raghu Mukkamala, MD
Internal Medicine · Montgomery, ALNPI 1720079395
Payments from drug & device makers
Across 146 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$439
- Novo Nordisk$329
- GSK$316
- Pfizer$266
- Lilly USA, LLC$211
- Amgen$142
- plus $873 from 24 others
What the payments were for
- Food & beverage$2,45895%
- Gifts$1195%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $439 |
| Novo Nordisk | 19 | $329 |
| GSK | 16 | $316 |
| Pfizer | 17 | $266 |
| Lilly USA, LLC | 14 | $211 |
| Amgen(2 entities) | 8 | $142 |
| Mannkind Corporation | 2 | $119 |
| Boehringer Ingelheim | 6 | $105 |
| Abbott | 5 | $91 |
| AbbVie | 4 | $68 |
| Bayer | 4 | $67 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Johnson & Johnson | 3 | $43 |
| Dexcom, Inc. | 2 | $32 |
| Neurocrine Biosciences, Inc. | 1 | $30 |
| Sumitomo Pharma America, Inc. | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Philips North America LLC | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Exact Sciences | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Braemar Manufacturing, LLC | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Eisai Inc. | 1 | $12 |
| Merck | 1 | $12 |
How this compares
$2,577 in reported general payments places this provider in the 75th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 235 | $238,995 |
| MounjaroTirzepatide | 185 | $220,814 |
| EliquisApixaban | 223 | $196,930 |
| JardianceEmpagliflozin | 186 | $194,859 |
| JanuviaSitagliptin Phosphate | 126 | $138,149 |
| XareltoRivaroxaban | 69 | $55,608 |
| TrulicityDulaglutide | 43 | $47,163 |
| FarxigaDapagliflozin Propanediol | 52 | $40,223 |
| LinzessLinaclotide | 32 | $27,613 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $24,717 |
| MyrbetriqMirabegron | 25 | $19,714 |
| Repatha SureclickEvolocumab | 22 | $15,171 |
| Atorvastatin Calcium | 934 | $15,085 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $15,040 |
| Victoza 3-PakLiraglutide | 13 | $14,792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $211 | $267,977228 claims |
| Novo NordiskOzempic | $329 | $238,995235 claims |
| PfizerEliquis, Paxlovid | $266 | $199,694250 claims |
| Boehringer IngelheimJardiance | $105 | $194,859186 claims |
| MerckJanuvia, Janumet Xr | $12 | $153,189140 claims |
| Johnson & JohnsonXarelto | $43 | $55,60869 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $439 | $53,81781 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $316 | $32,85545 claims |
| AbbVieLinzess | $68 | $27,61332 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $19,71425 claims |
| NovartisEntresto | $14 | $9,64011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Montgomery
- John PorterMontgomery$316K
- Joel McCloudMontgomery$27K
- John JerniganMontgomery$25K
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.